Document:

Exhibit 4.3

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

The following description of the securities of Oramed Pharmaceuticals
Inc. (the “Company”) is a summary only. This summary is not complete and is subject to and qualified by the provisions
of the Company’s Certificate of Incorporation, as amended (the “Charter”), and Amended and Restated By-laws,
as amended (the “By-laws”), which are filed as exhibits to the Company’s Annual Report on Form 10-K for the fiscal
year ended August 31, 2019 and are incorporated by reference herein.

 

Common Stock

 

Pursuant to the Company’s Charter, the Company is authorized
to issue up to thirty million (30,000,000) shares of common stock, par value $0.012 per share (the “Common Stock”).

 

The Common Stock is traded on The Nasdaq Capital Market and
the Tel Aviv Stock Exchange, in each case under the symbol “ORMP”.

 

The holders of shares of Common Stock vote together as one class
on all matters as to which holders of Common Stock are entitled to vote. Except as otherwise required by applicable law, all voting
rights are vested in and exercised by the holders of Common Stock with each share of Common Stock being entitled to one vote, including
in all elections of directors. The Company does not have a classified board of directors (the “Board”).

 

The holders of Common Stock are entitled to receive ratably
such dividends, if any, as may be declared from time to time by the Board out of legally available funds therefore. The Company
has not declared any dividends on its Common Stock and does not anticipate paying any dividends on its Common Stock in the foreseeable
future.

 

In the event of the Company’s liquidation, dissolution
or winding up, holders of the Common Stock are entitled to share ratably in all assets remaining after payment of liabilities.
The Common Stock has no cumulative voting rights and no preemptive or other rights to subscribe for shares of the Company.

 

There are no redemption or sinking fund provisions applicable
to the Common Stock. All shares of Common Stock currently outstanding are fully paid and non-assessable.

 

The Company is permitted to issue, and has from time to time,
issued warrants and options to purchase shares of the Common Stock, as well as restricted stock units.

 

Anti-Takeover Effects of the Company’s Charter and
By-Laws

 

In addition to provisions under Delaware law, the Company’s
Charter and By-Laws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender
offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, the
Charter and/or By-Laws, as applicable, among other things:

 

		·	provide the Board with the exclusive authority to call special meetings of the stockholders;

		·	provide the Board with the ability to alter the By-Laws without stockholder approval;

		·	provide the Board with the exclusive authority to fix the number of directors constituting the whole Board; and

		·	provide that vacancies on the Board may be filled by a majority of directors in office, although less than a quorum.

 

Such provisions may have the effect of discouraging a third-party
from acquiring the Company, even if doing so would be beneficial to the Company’s stockholders. These provisions are intended
to enhance the likelihood of continuity and stability in the composition of the Board and in its policies, and to discourage some
types of transactions that may involve an actual or threatened change in control of the Company. These provisions are designed
to reduce the Company’s vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used
in proxy fights. The Company believes that the benefits of increased protection of its potential ability to negotiate with the
proponent of an unfriendly or unsolicited proposal to acquire or restructure the Company outweigh the disadvantages of discouraging
such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms. However,
these provisions could have the effect of discouraging others from making tender offers for shares of the Company’s Common
Stock and, as a consequence, they also may inhibit fluctuations in the market price of the shares of the Company’s Common
Stock that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes
in the Company’s management.Exhibit 10.17

 

ORAMED PHARMACEUTICALS INC. 2019 STOCK
INCENTIVE PLAN

 

NOTICE OF STOCK OPTION AWARD

 

You have been granted an option to purchase
shares of Common Stock, subject to the terms and conditions of this Notice of Stock Option Award (the “Notice”), the
Oramed Pharmaceuticals Inc. 2019 Stock Incentive Plan, as amended from time to time (the “Plan”), and the Stock Option
Award Agreement (the “Option Agreement”) attached hereto, as follows. Unless otherwise defined herein or in the Option
Agreement, capitalized terms used herein shall have the respective meaning ascribed to such terms in the Plan.

 

	Grantee’s Name and Address:	 
	 	 
	 	____________________
	 	 
	Date of Award: 	 
	 	 
	Vesting Commencement Date: 	 
	 	 
	Exercise Price per Share: 	 
	 	 
	Total Number of Shares Subject to the Option (the “Shares”):
	 	 
	Total Exercise Price: 	 
	 	 
	Type of Option: 	102 Option/Non-qualified Option
	 	 
	Expiration Date: 	 

 

Vesting Schedule:

 

Subject to Grantee’s continued engagement
by Oramed Pharmaceuticals Inc., or one of its subsidiaries (“Oramed”), and other limitations set forth in this Notice,
the Plan and the Option Agreement, the Option may be exercised, in whole or in part, in accordance with the following vesting schedule:

  

	Installment	 	Number of Options	 	Vesting Date
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Total	 	 	 	 

 

     

     

    

 

IN WITNESS WHEREOF, the Company and the
Grantee have executed this Notice and agree that the Option is to be governed by the terms and conditions of this Notice, the Plan
and the Option Agreement.

 

	 	ORAMED PHARMACEUTICALS INC.
	 	a Delaware corporation
	 	 	 	 
	 	 	By:	           
	 	 	Name: 	Nadav Kidron
	 	 	Title: 	President and Chief Executive Officer

  

The Grantee acknowledges receipt of a copy
of the Plan and the Option Agreement, and represents that he or she is familiar with the terms and provisions thereof, and hereby
accepts the Option subject to all of the terms and provisions hereof and thereof. The Grantee has reviewed this Notice, the Plan
and the Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice,
and fully understands all provisions of this Notice, the Plan and the Option Agreement. The Grantee hereby agrees that all disputes
arising out of or relating to this Notice, the Plan and the Option Agreement shall be resolved in accordance with Section 10
of the Option Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated in
this Notice.

 

	Dated: ______________________	 	Signed: _________________________________

 

    2

     

    

 

ORAMED PHARMACEUTICALS, INC.

 

STOCK OPTION AWARD AGREEMENT

 

1. Grant
of Option. Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), hereby grants to the Grantee (the
“Grantee”) named in the Notice of Stock Option Award which is attached to this Stock Option Award Agreement (the “Notice”),
an option (the “Option”) to purchase the Total Number of Shares of Common Stock subject to the Option (the “Shares”)
set forth in the Notice, at the Exercise Price per Share set forth in the Notice (the “Exercise Price”) subject to
the terms and provisions of the Notice, this Stock Option Award Agreement (the “Option Agreement”) and the Company’s
2019 Stock Incentive Plan, as amended from time to time (the “Plan”), which are incorporated herein by reference. The
Company, during the term of the Option, will at all times reserve and keep available such number of Shares as shall be sufficient
to satisfy the requirements of the Option. Unless otherwise defined herein, capitalized terms use herein shall have the respective
meanings ascribed to such terms in the Plan. If so provided in the “Grant Type” shown in the Notice, this Option is
intended to constitute for United States income tax purposes an Incentive Stock Option and to qualify for the special United States
federal income tax treatment under Section 422 of the Code and upon exercise, the maximum number of shares that can be treated
as Incentive Stock Options shall be so treated, and the remainder shall be treated as Non-qualified Stock Options.

 

2. Exercise
of Option.

 

(a) Right
to Exercise. The vested portion of the Option shall be exercisable during its term in accordance with the Vesting Schedule
set out in the Notice and with the applicable provisions of the Plan and this Option Agreement. The Grantee’s employment,
contractual or other service relationship with the Company or its affiliates (“Relationship”) must be in effect on
a given date in order for any scheduled increment in vesting to become effective. In the event the Relationship is terminated for
any reason (whether voluntary or involuntary), (i) the Grantee’s right to vest in the Option will, except as explicitly provided
by the Board, terminate as of the date of termination of the Relationship (and such right shall not be extended by any notice period
mandated under local law), (ii) the Grantee’s continuing right (if any) to exercise the Option after termination of the Relationship
will be measured from the date of termination of the Relationship (and such right will not be extended by any notice period mandated
under local law) and (iii) the Board shall have the exclusive discretion to determine when the Relationship has terminated for
purposes of this Option (including determining when the Grantee is no longer considered to be providing active service while on
a leave of absence).

 

(b) Adjustments
of Award Upon Change in Control. The Option shall be subject to the provisions of Section 13 of the Plan relating to the vesting
and exercisability of the Option in the event of a Change in Control.

 

    3

     

    

 

(c) Method
of Exercise. The vested portion of the Option shall be exercisable by delivery of an exercise notice (a form of which is attached
as Exhibit A) which shall state the election to exercise the Option, the whole number of Shares in respect of which the Option
is being exercised, and such other provisions as set forth in Exhibit A. The exercise notice shall be delivered in person, by certified
mail, or by such other reasonable method (including electronic transmission) accompanied by payment of the Exercise Price and all
applicable income and employment taxes required to be withheld. The vested portion of the Option shall be deemed to be exercised
upon receipt by the Company of such notice accompanied by the Exercise Price and all applicable withholding taxes, which, to the
extent selected, shall be deemed to be satisfied by use of the broker-dealer sale and remittance procedure to pay the Exercise
Price provided in Section 3(d) below to the extent such procedure is available to the Grantee at the time of exercise and such
an exercise would not violate any applicable law.

 

As soon as practicable after its receipt of
the notice and Exercise Price and all applicable withholding taxes, the Company shall (a) deliver to the Grantee (or other person
entitled to exercise this Option), at the principal executive offices of the Company or such other place as shall be mutually acceptable,
a stock certificate or certificates for such shares out of theretofore authorized but unissued shares or treasury shares of its
Shares as the Company may elect or (b) issue shares of its Shares in book entry form. If the Grantee (or other person entitled
to exercise this Option) fails to pay for and accept delivery of all of the shares specified in the notice upon tender of delivery
thereof, his or her right to exercise this Option with respect to such shares not paid for may be terminated by the Company. In
no event shall the Company issue fractional Shares.

 

(d) Taxes.
No Shares will be delivered to the Grantee or other person pursuant to the exercise of the Option until the Grantee or other person
has made reasonable arrangements for the satisfaction of applicable income tax and employment tax withholding obligations, including,
without limitation, such other tax obligations of the Grantee incident to the receipt of Shares. Upon exercise of the Option, the
Company or the Grantee’s employer may offset or withhold (from any amount owed by the Company or the Grantee’s employer
to the Grantee) or collect from the Grantee or other person an amount sufficient to satisfy such tax withholding obligations.

 

3. Method
of Payment. Payment of the Exercise Price shall be made by any of the following, or a combination thereof, at the election
of the Grantee; provided, however, that such exercise method does not then violate any applicable law:

 

(a) cash;

 

(b) check;

 

(c) surrender
of Shares or delivery of a properly executed form of attestation of ownership of Shares which have a Fair Market Value on the date
of surrender or attestation equal to the aggregate Exercise Price of the Shares as to which the Option is being exercised;

 

(d) payment
through a broker-dealer sale and remittance procedure pursuant to which the Grantee (i) shall provide written instructions to a
Company-designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company
sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (ii) shall provide written directives
to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale
transaction;

 

    4

     

    

 

(e) with
respect to a Non-qualified Stock Option, payment through a “net exercise” such that, without the payment of any funds,
the Grantee may exercise the Option and receive the net number of Shares equal to (i) the number of Shares as to which the Option
is being exercised, multiplied by (ii) a fraction, the numerator of which is the Fair Market Value per Share (on such date as is
determined by the Administrator) less the Exercise Price, and the denominator of which is such Fair Market Value per Share (the
number of net Shares to be received shall be rounded down to the nearest whole number of Shares) and, at the election of the Grantee,
less (iii) such number of Shares as is equal to the withholding obligation provided in Section 2(d); or

 

(f) any
combination of the foregoing methods of payment.

 

4. Expiration
of Option. The Option must be exercised no later than the Expiration Date set forth in the Notice (the “Expiration Date”).
After the Expiration Date, the Option shall be of no further force or effect and may not be exercised. The Option may not be exercised
if the issuance of the Shares subject to the Option upon such exercise would constitute a violation of any Applicable Laws.

 

This Option may not be exercised after three
(3) months following the date of termination of the Relationship, except that if the Relationship terminates by reason of the Grantee’s
death or total and permanent disability (as determined by the Board on the basis of medical advice satisfactory to it), the unexercised
portion of the Option that is otherwise exercisable on the date of termination of the Relationship shall remain exercisable thereafter
for twelve (12) months. It is the Grantee’s responsibility to be aware of the date the Option expires.

 

5. Transferability
of Option. The Option may not be transferred in any manner other than by will or by the laws of descent and distribution and
may be exercised during the lifetime of the Grantee only by the Grantee; provided, however, that the Grantee may designate a beneficiary
of the Grantee’s Option in the event of the Grantee’s death on a beneficiary designation form provided by the Administrator.
No transfer permitted hereby shall be effective to bind the Company unless the Administrator has been furnished with written notice
of such transfer and an authenticated copy of the will and/or such other evidence as the Administrator may deem necessary to establish
the validity of the transfer and the acceptance by the transferee of the terms and conditions of such Award. The terms of the Option
shall be binding upon the executors, administrators, heirs, successors and transferees of the Grantee.

 

6. Adjustment
Upon Changes in Capitalization. Subject to any required action by the stockholders of the Company, the number of Shares covered
by this Option and the Exercise Price shall be proportionately adjusted as provided under Section 12 of the Plan.

 

7. Tax
Consequences. The Grantee may incur tax liability as a result of the Grantee’s purchase or disposition of the Shares.
THE GRANTEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.

 

    5

     

    

 

8. Entire
Agreement: Governing Law. This Option Agreement constitutes the entire agreement of the parties with respect to the subject
matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect
to the subject matter hereof, and may not be modified adversely to the Grantee’s interest except by means of a writing signed
by the Company and the Grantee. Nothing in this Award Agreement (except as expressly provided therein) is intended to confer any
rights or remedies on any persons other than the parties. This Award Agreement is to be construed in accordance with and governed
by the laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws
of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties. Should any provision
of this Award Agreement be determined to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed
by law and the other provisions shall nevertheless remain effective and shall remain enforceable.

 

9. Construction.
The captions used in this Option Agreement are inserted for convenience and shall not be deemed a part of the Option for construction
or interpretation. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include
the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise.
This Option Agreement is to be construed in accordance with the terms of the Plan. In case of any conflict between the Plan and
this Option Agreement, the Plan shall control. Capitalized terms not defined herein shall have the meanings given to them in the
Plan.

 

10. Venue
and Waiver of Jury Trial. The Company, the Grantee, and the Grantee’s assignees (the “parties”) agree that
any suit, action, or proceeding arising out of or relating to this Award Agreement shall be brought in the United States District
Court for the District of Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware
Court of Chancery) and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest
extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought
in such court. THE PARTIES ALSO EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH SUIT, ACTION OR PROCEEDING.
If any one or more provisions of this Section 10 shall for any reason be held invalid or unenforceable, it is the specific intent
of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.

 

11. Notices.
Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery,
upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail
by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at
its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to
the other party.

 

12. Rights
as Shareholder. The Grantee shall have no rights as a shareholder with respect to any shares covered by this Option until the
date of issuance of a stock certificate(s) (or appropriate book entry(ies) is(are) made in the case of book entry form) to him
or her for such shares. Except as otherwise provided pursuant to the Plan, no adjustment shall be made for dividends or other rights
for which the record date is prior to the date such stock certificate is issued (or appropriate entry is made in the case of book
entry form).

 

    6

     

    

 

13. Notice
of Disqualifying Disposition. If the “Grant Type” shown in the Customizing Information indicates that the Option
is an Incentive Stock Option, the Grantee agrees to notify the Company promptly in the event that he or she sells, transfers, exchanges
or otherwise disposes of any shares of Shares issued upon exercise of the Option before the later of (a) the second anniversary
of the date of grant of the Option and (b) the first anniversary of the date the shares were issued upon his or her exercise of
the Option.

 

14. Amendment;
Waivers. This Option Agreement, including the Plan, contains the full and complete understanding and agreement of the parties
hereto as to the subject matter hereof, and except as otherwise permitted by the express terms of the Plan, this Option Agreement
and applicable law, it may not be modified or amended nor may any provision hereof be waived without a further written agreement
duly signed by each of the parties; provided, however, that a modification or amendment that does not materially diminish the rights
of the Grantee hereunder, as they may exist immediately before the effective date of the modification or amendment, shall be effective
upon written notice of its provisions to the Grantee, to the extent permitted by applicable law. The waiver by either of the parties
hereto of any provision hereof in any instance shall not operate as a waiver of any other provision hereof or in any other instance.
The Grantee shall have the right to receive, upon request, a written confirmation from the Company of the Customizing Information.

 

15. Data
Privacy. By entering into this Option Agreement and except as otherwise provided in any data transfer agreement entered
into by the Company, the Grantee: (i) authorizes the Company, and any agent of the Company administering the Plan or providing
Plan recordkeeping services, to disclose to the Company such information and data as the Company shall request in order to facilitate
the grant of options and the administration of the Plan; (ii) waives any data privacy rights he or she may have with respect to
such information; and (iii) authorizes the Company to store and transmit such information in electronic form. For purposes of this
Section, the term “Company” refers to the Company and any affiliate.

 

    7

     

    

 

EXHIBIT A

 

ORAMED PHARMACEUTICALS, INC.

 

EXERCISE NOTICE

 

Oramed Pharmaceuticals Inc.

 

1185 Avenue of the Americas, Suite 228

New York, NY 10036

USA

 

Attention: Chief Executive Officer

 

1. Exercise of Option.
Effective as of today,___________ ___ , ___  the undersigned (the “Grantee”) hereby elects to exercise the
Grantee’s option to purchase ___________ shares of the Common Stock (the “Shares”) of Oramed Pharmaceuticals
Inc. (the “Company”) under and pursuant to the Company’s 2019 Stock Incentive Plan (the “Plan”)
and the Stock Option Award Agreement (the “Option Agreement”) dated _______________. Unless otherwise defined herein,
the terms defined in the Plan shall have the same defined meanings in this Exercise Notice.

 

2. Representations
of the Grantee. The Grantee acknowledges that the Grantee has received, read and understood the Plan and Award Agreement and
agrees to abide by and be bound by their terms and conditions.

 

3. Rights
as Stockholder. Until the stock certificate evidencing such Shares is issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other
rights as a stockholder shall exist with respect to the Shares, notwithstanding the exercise of the Option. The Company shall issue
(or cause to be issued) such stock certificate promptly after the Option is exercised. No adjustment will be made for a dividend
or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section 12
of the Plan.

 

4. Delivery
of Payment. The Grantee herewith delivers to the Company the full Exercise Price for the Shares, which, to the extent selected,
shall be deemed to be satisfied by use of the broker-dealer sale and remittance procedure to pay the Exercise Price provided in
Section 3(d) of the Option Agreement, if available.

 

5. Tax
Consultation. The Grantee understands that the Grantee may suffer adverse tax consequences as a result of the Grantee’s
purchase or disposition of the Shares. The Grantee represents that the Grantee has consulted with any tax consultants the Grantee
deems advisable in connection with the purchase or disposition of the Shares and that the Grantee is not relying on the Company
for any tax advice.

 

6. Taxes.
The Grantee agrees to satisfy all applicable foreign, federal, state and local income and employment tax withholding obligations
and herewith delivers to the Company the full amount of such obligations or has made arrangements acceptable to the Company to
satisfy such obligations.

 

    8

     

    

 

7. Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this
agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein
set forth, this Exercise Notice shall be binding upon the Grantee and his or her heirs, executors, administrators, successors and
assigns.

 

8. Construction.
The captions used in this Exercise Notice are inserted for convenience and shall not be deemed a part of this agreement for construction
or interpretation. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include
the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise.

 

9. Governing
Law; Severability. This Exercise Notice is to be construed in accordance with and governed by the internal laws of the State
of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other
than the laws of the State of Delaware to the rights and duties of the parties. Should any provision of this Exercise Notice be
determined by a court of law to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by
law and the other provisions shall nevertheless remain effective and shall remain enforceable.

 

10. Notices.
Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery,
upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail
by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at
its address as shown below beneath its signature, or to such other address as such party may designate in writing from time to
time to the other party.

 

11. Further
Instruments. The parties agree to execute such further instruments and to take such further action as may be reasonably necessary
to carry out the purposes and intent of this agreement.

 

12. Entire
Agreement. The Plan and the Award Agreement are incorporated herein by reference and together with this Exercise Notice constitute
the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings
and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the
Grantee’s interest except by means of a writing signed by the Company and the Grantee. Nothing in the Plan, Option Agreement
and this Exercise Notice (except as expressly provided therein) is intended to confer any rights or remedies on any persons other
than the parties.

 

	Submitted by:	Accepted by:
	 
	GRANTEE:	ORAMED PHARMACEUTICALS INC.
	 	 
	(Signature)	By:	                      
	 	 	Name:

Title:

 

	Address:	 	Address:
	 	 	 
	 	 	
        1185 Avenue of the Americas, Suite 228

        New York, NY 10036

        USA

	               	 	 

  

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]